Pathology of e-cigarettes and vaping-associated lung injury
Expires February 11, 2023
Video length: 43 minutes
In this month’s “Virtual Lecture,” Yasmeen Butt, M.D., describes the pathology of e-cigarette or vaping product use-associated lung injury (EVALI), reviews how to assess biopsies of suspected EVALI cases, and discusses the controversies surrounding an EVALI diagnosis.
Upon completion of this program, participants should be able to:
- Describe the pathology of e-cigarettes.
- Assess biopsies of suspected EVALI cases.
- Compare the findings of EVALI with other potential diagnoses in the differential.
- Describe the controversies surrounding this diagnosis, including potential ancillary testing.
This program is appropriate for clinicians, pathologists, medical technologists, nurses, pharmacists, and other allied health staff.
Assistant Professor of Laboratory Medicine and Pathology
Mayo Clinic, Scottsdale, Arizona
The following types of credit are offered for this program:
Mayo Clinic Laboratories is approved as a provider of continuing education programs in the Clinical Laboratory Sciences by the ASCLS P.A.C.E.® program. This program has been approved for a maximum of 1.0 P.A.C.E.® contact hour.
State of California
Mayo Clinic Laboratories is approved as a Continuing Education Accrediting Agency for Clinical Laboratory Sciences for the State of California. This program has been approved for 1.0 contact hour.
State of Florida
Mayo Clinic Laboratories is approved as a Continuing Education Accrediting Agency for the Clinical Laboratory Sciences for the State of Florida. Florida Board of Clinical Laboratory Personnel has designated this program for General credit. This program has been approved for 1.0 contact hour.
To obtain credit:
- Watch the video.
- Complete the post-test and evaluation that launches immediately following the video.
- Generate and print your certificate(s).
Level of instruction for this program is intermediate.
Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.
Contact us: firstname.lastname@example.org